Page last updated: 2024-11-04

sb 220025 and Neoplasms

sb 220025 has been researched along with Neoplasms in 1 studies

SB 220025: inhibits p38 mitogen-activated protein kinase; structure in first source
SB220025 : Am member of the class of imidazoles carrying piperidin-4-yl, 4-fluophenyl and 2-aminopyrimidin-4-yl substituents at posiitons 1, 4 and 5 respectively.

Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Park, H1
Bahn, YJ1
Jeong, DG1
Woo, EJ1
Kwon, JS1
Ryu, SE1

Other Studies

1 other study available for sb 220025 and Neoplasms

ArticleYear
Identification of novel inhibitors of extracellular signal-regulated kinase 2 based on the structure-based virtual screening.
    Bioorganic & medicinal chemistry letters, 2008, Oct-15, Volume: 18, Issue:20

    Topics: Adenosine Triphosphate; Antineoplastic Agents; Binding Sites; Chemistry, Pharmaceutical; Drug Design

2008